Akèy › Kansè nan tete › Oregon › Portland
Etid klinik pou Kansè nan tete nan Portland, OR
33 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Portland (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Ap rekriteFaz 3
- Oregon Health & Science University, Knight Cancer Institute, Portland
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Oregon Health & Science University (OHSU), Portland
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Ap rekriteFaz 3
- Northwest Cancer Specialists, Portland
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mi lwen
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Ap rekriteFaz 1/2
- Compass Oncology - Rose Quarter Cancer Center, Portland
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Ap rekriteFaz 1
- Research Site, Portland
Study of AVZO-021 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, Portland
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Ap rekriteFaz 3
- Providence Portland Medical Center ( Site 0044), Portland
- Providence St. Vincent Medical Center ( Site 0081), Portland
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Ap rekriteFaz 2
- Oregon Health and Science University, Portland
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Ap rekriteFaz 3
- Clinical Trial Site, Portland
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Ap rekriteFaz 3
- Oregon Health and Science University, Portland
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Ap rekriteFaz 2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Ap rekriteFaz 3
- Providence Portland Medical Center, Portland
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- Providence Cancer Institute Franz Clinic, Portland
- Providence Cancer Institute Franz Clinic, Portland
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Providence Portland Medical Center, Portland
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- Providence Cancer Institute, Portland
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Ap rekriteFaz 3
- Providence Portland Medical Center, Portland
- Providence Oncology and Hematology Cancer Clinic - Westside;Investigation Drug Services Pharmacy, Portland
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- ak 2 plis
A Study of MGC026 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Providence Cancer Institute, Portland
E-Mindfulness Approaches for Living After Breast Cancer
Ap rekriteFaz 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- ak 1 plis
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- Compass Oncology - Rose Quarter, Portland
Identifying and Caring for Individuals With Inherited Cancer Syndrome
Ap rekriteVolontè an sante akeyi
- Providence Portland Medical Center, Portland
- OHSU Knight Cancer Institute, Portland
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Providence Cancer Institute Franz Clinic, Portland
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Ap rekriteFaz 2
- OHSU Knight Cancer Institute, Portland
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Ap rekriteFaz 2
- Oregon Health & Science Institute (OHSU), Portland
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- ak 1 plis
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Kaiser Permanente Northwest, Portland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Oregon Health Sciences University, Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Portland
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Ap rekriteFaz 3
- Kaiser Permanente Northwest, Portland
- Oregon Health and Science University, Portland
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Ap rekriteEtid obsèvasyon
- Legacy Good Samaritan Medical Center, Portland
EMBRACE: Exercising Together
Ap rekriteFaz 2Volontè an sante akeyi
- OHSU Knight Cancer Institute, Portland
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Portland
- Kansè Poumon ki pa ti selil46 etid
- Kansè (tout kalite)34 etid
- Kansè pwostat33 etid
- Kansè Metastatik29 etid
- Kansè kolorektal28 etid
- Kansè ovè27 etid
- Kansè poumon26 etid
- Leksemi mieloïd egi25 etid
- Kansè Endomèt24 etid
- Karsinòm selil skuamèz tèt ak kou19 etid
- Kansè pankreyas19 etid
- Ensifizyans kadyak17 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.